← Eichor
Study identifier: NCT02997709 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients

Condition: Prostate Cancer  ·  Sponsor: University of Miami

PhaseN/A
Planned participants144
Who can joinMale, 30 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this research study is to learn about: 1) How standard radiation treatment to prostate (primary radiotherapy) or the pelvis after prostatectomy (postoperative radiotherapy) may cause changes in MRI and PET imaging traits that might be used in the future to predict response. 2) Comparison of such MRI and PET imaging traits with the number of circulating tumor cells (CTCs) present in the blood prior to treatment and the changes in these counts after treatment. 3) How MRI and PET imaging characteristics and changes are related to the expression of genes in the cancer tissue obtained before treatment from prostate biopsy or a prior prostatectomy before treatment. 4) How the response of prostate cancer treatment relates to the imaging and CTC changes.

This description comes directly from the study's public registry record.

Talk to the study team

Pavel Noa Hechevarria  ·  305-243-1036  ·  pavel.noa@med.miami.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of MiamiMiami, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02997709